

Atty. Dkt No. APF 30.20  
USSN: 09/421,778  
PATENT

### AMENDMENT

#### In the Claims:

Please amend claims 1, 7 and 25 as follows:

B<sup>1</sup>

1. (Amended) A method of obtaining expression in mammalian cells of [a polypeptide] an antigen of interest, which method comprises transferring into said cells a nucleic acid construct comprising a minimal promoter sequence operably linked to a coding sequence for the [polypeptide] antigen, whereafter said coding sequence is expressed in said mammalian cells.

B<sup>2</sup>

7. (Amended) A method according to claim 1, wherein the [polypeptide] antigen is [an antigen] a full length protein.

B<sup>3</sup>

25. (Amended) A nucleic acid construct comprising a minimal promoter sequence operably linked to a coding sequence for an antigen of interest.

### REMARKS

#### Introductory Comments:

Claims 1-27 are pending in the application. Claims, 9, 10, 18 and 19 have been withdrawn from consideration, and claims 1-8, 11-17 and 20-27 were examined in the Office Action dated 4 October 2000. More particularly, restriction has been required under 35 U.S.C. §121 to one of three groups of claims. Claims belonging to either of the two nonelected groups have been withdrawn from further consideration by the Office under 37 C.F.R. 1.142(b). In addition, the following claim rejections have been entered: (1) claims 1-5, 7, 8 and 11-14 were rejected under 35 U.S.C. §112, first paragraph, as nonenabled; (2) claim 6 was rejected under 35 U.S.C. §112, first paragraph, as nonenabled; (3) claims 1-8, 11-17 and 20-27 were rejected under 35 U.S.C. §112, second paragraph, as indefinite; (4) claims 1, 12-14 and 24-27 were